London, 4 May 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is proud to have supported its client, MaxCyte Inc. (LSE: MXCT), a global clinical-stage cell-based therapies and life sciences company, on the international communication of its £25.1 million fundraise.
MaxCyte are focussed on enabling the development of new medicines and bringing highly effective advanced therapies to the patients who desperately need them. The funds from this oversubscribed financing will allow MaxCyte to accelerate and strengthen its leading position as an enabler of next generation cell based therapies as it proceeds to a dual listing on NASDAQ. The fundraise, announced on Friday 1 May 2020, was led by international specialist healthcare crossover investors Casdin Capital and Sofinnova Partners.
“We are delighted to have supported MaxCyte through this recent successful cross-over financing and look forward to continuing to work closely with Doug, Ron and the team as they carry on their exciting journey.”
Mary-Jane Elliott
Managing Partner of Consilium Strategic Communications
“We are grateful to Consilium’s terrific support and help with this transaction. We sincerely appreciate M-J and the team’s professionalism and their diligent partnership with us.”
Doug Doerfler
President and Chief Executive Officer
The Consilium team representing MaxCyte Inc. on the financing news comprises Mary-Jane Elliott, Chris Welsh, Sarah Wilson and Aidina Brownlow.
MaxCyte’s announcement can be viewed in full here.
